Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Naratriptan | hsa00030 | Pentose phosphate pathway | 1.08E-04 | 4 | P60891, P51854, P52209, P37837 | PRPS1, TKTL1, PGD, TALDO1 | More | | Naratriptan | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Naratriptan | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Naratriptan | hsa00071 | Fatty acid degradation | 3.50E-02 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | | Naratriptan | hsa00190 | Oxidative phosphorylation | 5.12E-04 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Naratriptan | hsa00230 | Purine metabolism | 4.02E-02 | 2 | P31350, P21589 | RRM2, NT5E | More | | Naratriptan | hsa00240 | Pyrimidine metabolism | 2.54E-04 | 3 | P31350, P21589, P04818 | RRM2, NT5E, TYMS | More | | Naratriptan | hsa00500 | Starch and sucrose metabolism | 6.17E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Naratriptan | hsa00561 | Glycerolipid metabolism | 3.35E-02 | 2 | P14550, Q86XP1 | AKR1A1, DGKH | More | | Naratriptan | hsa00565 | Ether lipid metabolism | 1.77E-04 | 2 | Q9Y6K0, Q8N661 | CEPT1, TMEM86B | More | | Naratriptan | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Naratriptan | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Naratriptan | hsa00600 | Sphingolipid metabolism | 2.77E-02 | 3 | Q9BX95, Q8TCT0, P15289 | SGPP1, CERK, ARSA | More | | Naratriptan | hsa00630 | Glyoxylate and dicarboxylate metabolism | 5.34E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | Naratriptan | hsa00730 | Thiamine metabolism | 2.27E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Naratriptan | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Naratriptan | hsa00830 | Retinol metabolism | 2.20E-02 | 4 | P00325, P11766, Q9BPW9, O75911 | ADH1B, ADH5, DHRS9, DHRS3 | More | | Naratriptan | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | | Naratriptan | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Naratriptan | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Naratriptan | hsa00983 | Drug metabolism - other enzymes | 1.64E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Naratriptan | hsa01040 | Biosynthesis of unsaturated fatty acids | 2.92E-02 | 2 | P22307, Q9H5J4 | SCP2, ELOVL6 | More | | Naratriptan | hsa01100 | Metabolic pathways | 2.24E-02 | 13 | Q9Y234, Q6ZQY3, Q02153, P20839, Q9Y6K0, Q86XP1, P14550, Q9UHK6, Q86VZ5, Q9BVK2, P37837, Q99437, Q9NVH6 | LIPT1, GADL1, GUCY1B3, IMPDH1, CEPT1, DGKH, AKR1A1, AMACR, SGMS1, ALG8, TALDO1, ATP6V0B, TMLHE | More | | Naratriptan | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Naratriptan | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Naratriptan | hsa01522 | Endocrine resistance | 4.48E-02 | 4 | P22694, Q02750, Q9UM47, P46527 | PRKACB, MAP2K1, NOTCH3, CDKN1B | More | | Naratriptan | hsa01523 | Antifolate resistance | 6.06E-03 | 2 | Q92820, P04818 | GGH, TYMS | More | | Naratriptan | hsa01524 | Platinum drug resistance | 1.47E-03 | 3 | O15392, P11388, P31751 | BIRC5, TOP2A, AKT2 | More | | Naratriptan | hsa02010 | ABC transporters | 2.17E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | Naratriptan | hsa03015 | mRNA surveillance pathway | 4.42E-02 | 4 | O60942, O43148, P52298, Q53GS7 | RNGTT, RNMT, NCBP2, GLE1 | More | | Naratriptan | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | Naratriptan | hsa03020 | RNA polymerase | 1.37E-06 | 5 | P30876, P24928, P62487, Q9GZM3, P52435 | POLR2B, POLR2A, POLR2G, POLR2J2, POLR2J | More | | Naratriptan | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Naratriptan | hsa03040 | Spliceosome | 4.19E-02 | 5 | Q14562, O60508, P08579, Q01130, O43447 | DHX8, CDC40, SNRPB2, SFRS2, PPIH | More | | Naratriptan | hsa03060 | Protein export | 7.71E-04 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Naratriptan | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Naratriptan | hsa03460 | Fanconi anemia pathway | 4.83E-02 | 2 | Q9BXW9, P07992 | FANCD2, ERCC1 | More | | Naratriptan | hsa04014 | Ras signaling pathway | 5.91E-03 | 8 | Q02750, P31751, Q15389, P17252, P21359, P0DP23, P62879, P22694 | MAP2K1, AKT2, ANGPT1, PRKCA, NF1, CALM1, GNB2, PRKACB | More | | Naratriptan | hsa04015 | Rap1 signaling pathway | 6.14E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Naratriptan | hsa04022 | cGMP-PKG signaling pathway | 1.41E-03 | 6 | P18848, Q8WYR1, P31751, P05141, P0DP24, P0DP23 | ATF4, PIK3R5, AKT2, SLC25A5, CALM2, CALM1 | More | | Naratriptan | hsa04024 | cAMP signaling pathway | 3.23E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Naratriptan | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Naratriptan | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | | Naratriptan | hsa04064 | NF-kappa B signaling pathway | 6.41E-06 | 21 | Q13489, O00463, Q13546, P14778, P01584, P01375, P19174, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q8WV28, P63279, P24522, Q8NHW4, P09341, P19875, Q06643, Q9UNE0, Q9NQC7 | BIRC3, TRAF5, RIPK1, IL1R1, IL1B, TNF, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, BLNK, UBE2I, GADD45A, CCL4L2, CXCL1, CXCL2, LTB, EDAR, CYLD | More | | Naratriptan | hsa04066 | HIF-1 signaling pathway | 4.48E-02 | 4 | P17252, Q15389, Q02750, P46527 | PRKCA, ANGPT1, MAP2K1, CDKN1B | More | | Naratriptan | hsa04070 | Phosphatidylinositol signaling system | 1.53E-02 | 2 | Q86XP1, Q96DU7 | DGKH, ITPKC | More | | Naratriptan | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | | Naratriptan | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Naratriptan | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Naratriptan | hsa04110 | Cell cycle | 2.34E-02 | 3 | P06493, O60566, P33981 | CDK1, BUB1B, TTK | More | | Naratriptan | hsa04115 | p53 signaling pathway | 3.34E-02 | 2 | P31350, P06493 | RRM2, CDK1 | More | | Naratriptan | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Naratriptan | hsa04142 | Lysosome | 7.47E-05 | 9 | P06865, P22304, P38571, Q13510, Q9UJJ9, P07602, Q9NRA2, P49279, P61916 | HEXA, IDS, LIPA, ASAH1, GNPTG, PSAP, SLC17A5, SLC11A1, NPC2 | More | | Naratriptan | hsa04144 | Endocytosis | 2.00E-04 | 9 | P0DMV8, Q9H444, O75351, P62491, Q96B97, Q15438, Q8WU79, Q14161, Q9UMY4 | HSPA1A, CHMP4B, VPS4B, RAB11A, SH3KBP1, PSCD1, SMAP1L, GIT2, SNX12 | More | | Naratriptan | hsa04145 | Phagosome | 2.61E-02 | 5 | P63261, Q15080, P14598, Q13509, P68371 | ACTG1, NCF4, NCF1, TUBB3, TUBB2C | More | | Naratriptan | hsa04151 | PI3K-Akt signaling pathway | 7.39E-03 | 7 | P62753, O43521, P27348, Q8WYR1, P18848, O00141, Q6ZUJ8 | RPS6, BCL2L11, YWHAQ, PIK3R5, ATF4, SGK, PIK3AP1 | More | | Naratriptan | hsa04210 | Apoptosis | 3.63E-02 | 3 | O75460, O43521, P18848 | ERN1, BCL2L11, ATF4 | More | | Naratriptan | hsa04211 | Longevity regulating pathway | 1.18E-02 | 3 | Q12778, Q9UEF7, Q96KQ7 | FOXO1, KL, EHMT2 | More | | Naratriptan | hsa04213 | Longevity regulating pathway - multiple species | 4.52E-04 | 7 | P42338, Q9Y4H2, Q08828, P51828, P0DMV8, P11142, Q13547 | PIK3CB, IRS2, ADCY1, ADCY7, HSPA1A, HSPA8, HDAC1 | More | | Naratriptan | hsa04217 | Necroptosis | 7.45E-10 | 23 | P01375, P01568, P23458, P48023, Q13489, Q9NQC7, Q13546, P42224, Q14765, P08238, P15104, P05141, P01584, P07384, P0C0S5, Q6FI13, Q99878, Q93077, P10415, Q9H444, O43633, O75351, Q08752 | TNF, IFNA21, JAK1, FASLG, BIRC3, CYLD, RIPK1, STAT1, STAT4, HSP90AB1, GLUL, SLC25A5, IL1B, CAPN1, H2AFZ, H2AC18; H2AC19, H2AC14, HIST1H2AC, BCL2, CHMP4B, CHMP2A, VPS4B, PPID | More | | Naratriptan | hsa04218 | Cellular senescence | 3.65E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Naratriptan | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.83E-03 | 6 | P07550, P22694, P31751, P18848, Q13362, P0DP23 | ADRB2, PRKACB, AKT2, ATF4, PPP2R5C, CALM1 | More | | Naratriptan | hsa04270 | Vascular smooth muscle contraction | 2.36E-04 | 6 | P0DP23, Q08828, P51828, P35579, P35749, P35318 | CALM1, ADCY1, ADCY7, MYH9, MYH11, ADM | More | | Naratriptan | hsa04370 | VEGF signaling pathway | 3.60E-02 | 1 | P31751 | AKT2 | More | | Naratriptan | hsa04371 | Apelin signaling pathway | 3.23E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Naratriptan | hsa04380 | Osteoclast differentiation | 5.19E-06 | 14 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P31751, P01584, P14778, O75015, Q8WV28, P01375, Q15080, Q8N149, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, AKT2, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, LILRA2, SIRPA | More | | Naratriptan | hsa04510 | Focal adhesion | 4.64E-02 | 6 | O75369, Q15942, Q13489, P10415, P49767, P63261 | FLNB, ZYX, BIRC3, BCL2, VEGFC, ACTG1 | More | | Naratriptan | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Naratriptan | hsa04540 | Gap junction | 2.03E-02 | 4 | P17252, P22694, P68371, Q02750 | PRKCA, PRKACB, TUBB2C, MAP2K1 | More | | Naratriptan | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | | Naratriptan | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Naratriptan | hsa04613 | Neutrophil extracellular trap formation | 8.84E-04 | 19 | O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P04908, P0C0S5, Q93077, P62807, O60814, P68431, Q15080, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AC4; H2AC8, H2AFZ, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Naratriptan | hsa04614 | Renin-angiotensin system | 2.74E-02 | 3 | P15144, P08311, O75787 | ANPEP, CTSG, ATP6AP2 | More | | Naratriptan | hsa04620 | Toll-like receptor signaling pathway | 4.81E-03 | 3 | Q13546, P01568, P31751 | RIPK1, IFNA21, AKT2 | More | | Naratriptan | hsa04621 | NOD-like receptor signaling pathway | 4.72E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | | Naratriptan | hsa04622 | RIG-I-like receptor signaling pathway | 1.02E-03 | 3 | P01568, Q9NQC7, Q13546 | IFNA21, CYLD, RIPK1 | More | | Naratriptan | hsa04623 | Cytosolic DNA-sensing pathway | 3.54E-07 | 5 | P01584, P01568, Q13546, P25963, Q8NHW4 | IL1B, IFNA21, RIPK1, NFKBIA, CCL4L2 | More | | Naratriptan | hsa04625 | C-type lectin receptor signaling pathway | 1.92E-05 | 11 | Q9ULY5, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P31751, P0DP24, P0DP23, Q16539 | CLEC4E, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, AKT2, CALM2, CALM1, MAPK14 | More | | Naratriptan | hsa04640 | Hematopoietic cell lineage | 2.62E-03 | 14 | P13612, P14778, P27930, P11215, P15144, P11836, P25063, P07766, P09693, P01732, P09564, P13765, P01375, P01584 | ITGA4, IL1R1, IL1R2, ITGAM, ANPEP, MS4A1, CD24, CD3E, CD3G, CD8A, CD7, HLA-DOB, TNF, IL1B | More | | Naratriptan | hsa04650 | Natural killer cell mediated cytotoxicity | 3.46E-06 | 14 | P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, O75015, P26717, Q14953, P26715 | PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | | Naratriptan | hsa04657 | IL-17 signaling pathway | 1.06E-04 | 9 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375, P01584 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF, IL1B | More | | Naratriptan | hsa04658 | Th1 and Th2 cell differentiation | 2.95E-05 | 14 | Q04759, P07766, P20963, P09693, Q16539, P19174, P06239, Q14765, P23771, Q9UL17, P14784, P13765, P23458, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, JAK1, RUNX3 | More | | Naratriptan | hsa04659 | Th17 cell differentiation | 1.17E-04 | 14 | Q04759, Q16539, P19174, P06239, P14784, P13765, P14778, Q9UL17, P23771, P01584, P07766, P09693, P20963, P23458 | PRKCQ, MAPK14, PLCG1, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, IL1B, CD3E, CD3G, CD247, JAK1 | More | | Naratriptan | hsa04660 | T cell receptor signaling pathway | 1.96E-04 | 14 | P01375, Q04759, P42338, O95267, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Naratriptan | hsa04662 | B cell receptor signaling pathway | 1.60E-04 | 6 | P31751, P42338, P60033, P07948, P21854, Q8N149 | AKT2, PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Naratriptan | hsa04664 | Fc epsilon RI signaling pathway | 5.75E-04 | 7 | P01375, P31751, Q16539, P42338, Q9UQC2, P07948, P09917 | TNF, AKT2, MAPK14, PIK3CB, GAB2, LYN, ALOX5 | More | | Naratriptan | hsa04668 | TNF signaling pathway | 1.71E-04 | 9 | P01375, O00463, Q16539, P18848, P19875, P01584, P20749, P14780, P20333 | TNF, TRAF5, MAPK14, ATF4, CXCL2, IL1B, BCL3, MMP9, TNFRSF1B | More | | Naratriptan | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Naratriptan | hsa04720 | Long-term potentiation | 1.09E-02 | 4 | P17252, P51812, P22694, Q02750 | PRKCA, RPS6KA3, PRKACB, MAP2K1 | More | | Naratriptan | hsa04721 | Synaptic vesicle cycle | 4.76E-03 | 4 | Q13488, Q99437, P43005, P31645 | TCIRG1, ATP6V0B, SLC1A1, SLC6A4 | More | | Naratriptan | hsa04722 | Neurotrophin signaling pathway | 1.26E-03 | 5 | P31751, P49841, O43524, P48023, P0DP23 | AKT2, GSK3B, FOXO3, FASLG, CALM1 | More | | Naratriptan | hsa04724 | Glutamatergic synapse | 1.75E-04 | 6 | O15399, P51828, P62873, P63218, P50151, P15104 | GRIN2D, ADCY7, GNB1, GNG5, GNG10, GLUL | More | | Naratriptan | hsa04725 | Cholinergic synapse | 2.59E-03 | 7 | P22694, P17252, P62879, P63218, P50151, P42338, Q02750 | PRKACB, PRKCA, GNB2, GNG5, GNG10, PIK3CB, MAP2K1 | More | | Naratriptan | hsa04726 | Serotonergic synapse | 2.43E-02 | 4 | P22694, P17252, P62879, Q02750 | PRKACB, PRKCA, GNB2, MAP2K1 | More | | Naratriptan | hsa04727 | GABAergic synapse | 8.55E-05 | 9 | P51828, P62873, P62879, P63218, P50151, P15104, P22694, O60296, P17252 | ADCY7, GNB1, GNB2, GNG5, GNG10, GLUL, PRKACB, TRAK2, PRKCA | More | | Naratriptan | hsa04728 | Dopaminergic synapse | 3.23E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Naratriptan | hsa04740 | Olfactory transduction | 9.46E-04 | 2 | Q9H255, P0DP23 | OR51E2, CALM1 | More | | Naratriptan | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Naratriptan | hsa04744 | Phototransduction | 1.81E-02 | 1 | P0DP23 | CALM1 | More | | Naratriptan | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.66E-05 | 13 | P14778, P01584, Q08828, P51828, P22694, Q16539, P19174, P42338, Q14643, P24723, Q04759, P0DP24, P0DP23 | IL1R1, IL1B, ADCY1, ADCY7, PRKACB, MAPK14, PLCG1, PIK3CB, ITPR1, PRKCH, PRKCQ, CALM2, CALM1 | More | | Naratriptan | hsa04910 | Insulin signaling pathway | 9.82E-04 | 2 | P0DP23, P31751 | CALM1, AKT2 | More | | Naratriptan | hsa04912 | GnRH signaling pathway | 5.53E-03 | 8 | Q08828, P51828, Q16539, Q9Y6R4, Q14643, P0DP24, P0DP23, P22694 | ADCY1, ADCY7, MAPK14, MAP3K4, ITPR1, CALM2, CALM1, PRKACB | More | | Naratriptan | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Naratriptan | hsa04915 | Estrogen signaling pathway | 6.26E-05 | 6 | Q08828, P51828, P31751, P0DMV8, P0DP23, Q15788 | ADCY1, ADCY7, AKT2, HSPA1A, CALM1, NCOA1 | More | | Naratriptan | hsa04916 | Melanogenesis | 4.78E-02 | 1 | P0DP23 | CALM1 | More | | Naratriptan | hsa04917 | Prolactin signaling pathway | 2.41E-02 | 1 | P31751 | AKT2 | More | | Naratriptan | hsa04919 | Thyroid hormone signaling pathway | 2.22E-02 | 5 | P17252, Q02750, P22694, Q12778, Q9UM47 | PRKCA, MAP2K1, PRKACB, FOXO1, NOTCH3 | More | | Naratriptan | hsa04920 | Adipocytokine signaling pathway | 4.19E-02 | 1 | P31751 | AKT2 | More | | Naratriptan | hsa04922 | Glucagon signaling pathway | 1.79E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Naratriptan | hsa04923 | Regulation of lipolysis in adipocytes | 3.88E-03 | 4 | P07550, P42338, Q9Y4H2, P31751 | ADRB2, PIK3CB, IRS2, AKT2 | More | | Naratriptan | hsa04924 | Renin secretion | 6.94E-04 | 3 | P22694, P07550, P0DP23 | PRKACB, ADRB2, CALM1 | More | | Naratriptan | hsa04926 | Relaxin signaling pathway | 3.93E-04 | 9 | P42338, P63218, P50151, P18848, P22694, P49767, P14780, P30679, P49407 | PIK3CB, GNG5, GNG10, ATF4, PRKACB, VEGFC, MMP9, GNA15, ARRB1 | More | | Naratriptan | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Naratriptan | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.48E-02 | 4 | P22694, Q02750, P17252, Q9Y5Q3 | PRKACB, MAP2K1, PRKCA, MAFB | More | | Naratriptan | hsa04929 | GnRH secretion | 3.61E-03 | 3 | P42338, P31751, P49407 | PIK3CB, AKT2, ARRB1 | More | | Naratriptan | hsa04932 | Non-alcoholic fatty liver disease | 6.81E-07 | 12 | P01375, P49841, O43521, P18848, P48023, O75460, P01584, P13073, P12074, Q16718, O95298, O14521 | TNF, GSK3B, BCL2L11, ATF4, FASLG, ERN1, IL1B, COX4I1, COX6A1, NDUFA5, NDUFC2, SDHD | More | | Naratriptan | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Naratriptan | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Naratriptan | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | Naratriptan | hsa04970 | Salivary secretion | 3.34E-06 | 7 | P07550, Q08828, P51828, P22694, P17252, P0DP23, P49913 | ADRB2, ADCY1, ADCY7, PRKACB, PRKCA, CALM1, CAMP | More | | Naratriptan | hsa04971 | Gastric acid secretion | 4.78E-02 | 1 | P0DP23 | CALM1 | More | | Naratriptan | hsa04973 | Carbohydrate digestion and absorption | 4.61E-03 | 3 | O43451, P42338, P31751 | MGAM, PIK3CB, AKT2 | More | | Naratriptan | hsa04975 | Fat digestion and absorption | 2.80E-02 | 1 | O14494 | PLPP1 | More | | Naratriptan | hsa04976 | Bile secretion | 3.14E-03 | 5 | O43315, Q08828, P51828, P08183, Q14032 | AQP9, ADCY1, ADCY7, ABCB1, BAAT | More | | Naratriptan | hsa05010 | Alzheimer disease | 8.89E-04 | 9 | P13073, Q00535, O75460, P0DP24, P0DP23, P01584, P18848, P31751, P05141 | COX4I1, CDK5, ERN1, CALM2, CALM1, IL1B, ATF4, AKT2, SLC25A5 | More | | Naratriptan | hsa05012 | Parkinson disease | 3.89E-02 | 5 | P13073, P05141, O75460, P18848, P0DP24 | COX4I1, SLC25A5, ERN1, ATF4, CALM2 | More | | Naratriptan | hsa05016 | Huntington disease | 1.94E-05 | 13 | O95298, P13073, P12074, Q9GZM3, P24928, P30876, P62487, P52435, P05141, Q9NYC9, O75460, P28070, O00232 | NDUFC2, COX4I1, COX6A1, POLR2J2, POLR2A, POLR2B, POLR2G, POLR2J, SLC25A5, DNAH9, ERN1, PSMB4, PSMD12 | More | | Naratriptan | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Naratriptan | hsa05022 | Pathways of neurodegeneration - multiple diseases | 5.79E-05 | 21 | O15399, Q13509, P68371, P49841, P10415, Q16718, O14521, P13073, O75460, P18848, Q13561, P05141, P20333, Q16539, P07384, Q00535, P04628, P01584, Q08752, P0DP23, P0DP24 | GRIN2D, TUBB3, TUBB2C, GSK3B, BCL2, NDUFA5, SDHD, COX4I1, ERN1, ATF4, DCTN2, SLC25A5, TNFRSF1B, MAPK14, CAPN1, CDK5, WNT1, IL1B, PPID, CALM1, CALM2 | More | | Naratriptan | hsa05030 | Cocaine addiction | 4.19E-02 | 1 | Q00535 | CDK5 | More | | Naratriptan | hsa05031 | Amphetamine addiction | 6.98E-03 | 4 | P0DP23, P22694, P18848, Q13547 | CALM1, PRKACB, ATF4, HDAC1 | More | | Naratriptan | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Naratriptan | hsa05100 | Bacterial invasion of epithelial cells | 4.50E-02 | 1 | Q92529 | SHC3 | More | | Naratriptan | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.44E-04 | 7 | Q99437, P09341, P19875, P10145, P19174, P25024, P25025 | ATP6V0B, CXCL1, CXCL2, IL8, PLCG1, CXCR1, CXCR2 | More | | Naratriptan | hsa05132 | Salmonella infection | 3.09E-04 | 9 | P63261, Q13546, Q13489, P10415, O75369, Q13561, O60282, Q13509, P68371 | ACTG1, RIPK1, BIRC3, BCL2, FLNB, DCTN2, KIF5C, TUBB3, TUBB2C | More | | Naratriptan | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | | Naratriptan | hsa05134 | Legionellosis | 8.80E-04 | 7 | P01584, Q9NR31, P11215, P0DMV8, P11142, P09341, P19875 | IL1B, SAR1A, ITGAM, HSPA1A, HSPA8, CXCL1, CXCL2 | More | | Naratriptan | hsa05140 | Leishmaniasis | 1.29E-03 | 13 | P13612, O75015, P14598, P23458, P42224, P13765, O60603, P25963, P01375, P01584, P29350, Q16539, Q15080 | ITGA4, FCGR3B, NCF1, JAK1, STAT1, HLA-DOB, TLR2, NFKBIA, TNF, IL1B, PTPN6, MAPK14, NCF4 | More | | Naratriptan | hsa05143 | African trypanosomiasis | 3.77E-05 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Naratriptan | hsa05144 | Malaria | 1.48E-05 | 9 | P60033, P69905, P68871, O60603, P01375, P35443, P01584, P10145, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, IL1B, IL8, KLRK1 | More | | Naratriptan | hsa05146 | Amoebiasis | 1.27E-05 | 14 | P01584, P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P30679, P22694, P12814, P08311 | IL1B, CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | Naratriptan | hsa05152 | Tuberculosis | 9.92E-03 | 2 | P0DP23, P31751 | CALM1, AKT2 | More | | Naratriptan | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Naratriptan | hsa05162 | Measles | 3.18E-02 | 4 | P23458, P0DMV8, P01584, Q9NP90 | JAK1, HSPA1A, IL1B, RAB9B | More | | Naratriptan | hsa05163 | Human cytomegalovirus infection | 7.23E-04 | 14 | P31751, P01375, P0DP23, Q8NHW4, Q08828, P51828, P23458, P49841, P14778, P01584, Q13651, P25025, Q16539, O00463 | AKT2, TNF, CALM1, CCL4L2, ADCY1, ADCY7, JAK1, GSK3B, IL1R1, IL1B, IL10RA, CXCR2, MAPK14, TRAF5 | More | | Naratriptan | hsa05165 | Human papillomavirus infection | 4.71E-03 | 10 | P46527, Q02750, P35443, Q92796, Q05086, Q9UM47, P22694, Q13362, Q12778, Q13315 | CDKN1B, MAP2K1, THBS4, DLG3, UBE3A, NOTCH3, PRKACB, PPP2R5C, FOXO1, ATM | More | | Naratriptan | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 5.07E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Naratriptan | hsa05168 | Herpes simplex virus 1 infection | 1.40E-04 | 18 | Q9UKJ0, Q06124, P25963, P01568, Q05823, P42224, Q07955, Q01130, Q13243, Q13489, Q13398, Q9NR11, Q9HCX3, Q03923, P52738, O75820, Q9UDV6, P10415 | PILRB, PTPN11, NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, ZNF211, ZNF302, ZNF304, ZNF85, ZNF140, ZNF189, ZNF212, BCL2 | More | | Naratriptan | hsa05169 | Epstein-Barr virus infection | 3.72E-02 | 6 | Q13547, P42338, P07948, Q13761, O75293, P07766 | HDAC1, PIK3CB, LYN, RUNX3, GADD45B, CD3E | More | | Naratriptan | hsa05170 | Human immunodeficiency virus 1 infection | 6.71E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Naratriptan | hsa05200 | Pathways in cancer | 3.07E-02 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Naratriptan | hsa05202 | Transcriptional misregulation in cancer | 9.77E-05 | 23 | Q92570, Q12778, Q13315, O94812, P58340, P10145, P17844, P14780, P27930, Q15744, Q16548, Q13077, P46527, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | NR4A3, FOXO1, ATM, BAIAP3, MLF1, IL8, DDX5, MMP9, IL1R2, CEBPE, BCL2A1, TRAF1, CDKN1B, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | Naratriptan | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Naratriptan | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Naratriptan | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Naratriptan | hsa05206 | MicroRNAs in cancer | 3.66E-02 | 6 | P46527, Q9UM47, P16070, Q13315, P17252, Q02750 | CDKN1B, NOTCH3, CD44, ATM, PRKCA, MAP2K1 | More | | Naratriptan | hsa05211 | Renal cell carcinoma | 4.78E-02 | 1 | P31751 | AKT2 | More | | Naratriptan | hsa05212 | Pancreatic cancer | 4.78E-02 | 1 | P31751 | AKT2 | More | | Naratriptan | hsa05213 | Endometrial cancer | 3.60E-02 | 1 | P31751 | AKT2 | More | | Naratriptan | hsa05214 | Glioma | 5.75E-04 | 2 | P0DP23, P31751 | CALM1, AKT2 | More | | Naratriptan | hsa05217 | Basal cell carcinoma | 3.50E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Naratriptan | hsa05218 | Melanoma | 3.01E-02 | 1 | P31751 | AKT2 | More | | Naratriptan | hsa05220 | Chronic myeloid leukemia | 4.19E-02 | 1 | P31751 | AKT2 | More | | Naratriptan | hsa05221 | Acute myeloid leukemia | 4.19E-02 | 1 | P31751 | AKT2 | More | | Naratriptan | hsa05222 | Small cell lung cancer | 4.78E-02 | 1 | P31751 | AKT2 | More | | Naratriptan | hsa05223 | Non-small cell lung cancer | 2.41E-02 | 1 | P31751 | AKT2 | More | | Naratriptan | hsa05226 | Gastric cancer | 3.60E-02 | 1 | P31751 | AKT2 | More | | Naratriptan | hsa05230 | Central carbon metabolism in cancer | 4.78E-02 | 1 | P31751 | AKT2 | More | | Naratriptan | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.58E-03 | 11 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, P23458, O60603, Q04759, Q16539 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, JAK1, TLR2, PRKCQ, MAPK14 | More | | Naratriptan | hsa05321 | Inflammatory bowel disease | 7.47E-04 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B | More | | Naratriptan | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Naratriptan | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Naratriptan | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | | Naratriptan | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | Naratriptan | hsa05415 | Diabetic cardiomyopathy | 4.54E-04 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | | Naratriptan | hsa05418 | Fluid shear stress and atherosclerosis | 6.43E-05 | 9 | Q16539, P31751, Q14145, P10599, P14780, P01375, P14778, P27930, P0DP23 | MAPK14, AKT2, KEAP1, TXN, MMP9, TNF, IL1R1, IL1R2, CALM1 | More | | |